바이오인

 

 

EXECUTIVE SUMMARY

FOREWORD ........................................................................ 1-2
MBC: THE VOICE OF BIOTECHNOLOGY IN MASSACHUSETTS AND AROUND THE WORLD ...... 3
MBC’S 2015 VISION ANCHORED IN COLLABORATION .......................... 3
AREAS OF FOCUS ...................................... 4
MBC AND YOU: THE RIGHT COMBINATION ................................................ 4
STATE OF THE MASSACHUSETTS CLUSTER
THE MASSACHUSETTS BIOTECH CLUSTER: CONTINUING TO LEAD THROUGH TUMULTUOUS TIMES THE KEY COMPONENTS OF THE MA BIOTECH CLUSTER ...........................5
UNDERSTANDING THE GLOBAL LANDSCAPE .......................................5-6
UNDERSTANDING TRENDS THAT WILL SHAPE THE MA BIOTECH CLUSTER ..................7
UNDERSTANDING THE NEEDS OF MASSACHUSETTS STAKEHOLDERS ECONOMIC CHALLENGES UNDERSCORE THE NEED FOR COLLABORATIVE EFFORTS ......................8-10
ONE COMMUNITY, DIVERSE NEEDS .....................................................11
A VISION FOR 2015 PROMOTE INNOVATION BY FACILITATING CONNECTIONS AMONG KEY STAKEHOLDERS .......................12
IMPROVE ACCESS TO CAPITAL FOR COMPANIES IN NEAR AND LONG-TERM ..............13
PROVIDE SERVICES TO REDUCT BURN RATE AND ENABLE GROWTH ...................14
ENHANCE AND ACCELERATE EFFORTS TO ATTRACT, DEVELOP AND RETAIN TALENT .........15
IMPROVE COMPANY RECRUITMENT AND RETENTION EFFORTS ......................16
IMPROVE INDUSTRY REPRESENTATION THROUGH COLLABORATION WITH OTHER ORGANIZATIONS ...17
CONCRETE ACTIONS WILL PRODUCE TANGIBLE RESULTS WE NEED YOUR ACTIVE PARTICIPATION ....................................................18

 

 

In the short 30 years since biotechnology emerged as an independent science,
Massachusett s has risen as the world leader in the industry. We have att ained this stature
without a great deal of planning or strategy. For the most part, we have benefi tt ed from
the confl uence of world-class teaching hospitals and academic insti tuti ons, the talented
people those insti tuti ons produce, and a robust venture capital community. This positi on
can not be maintained, however, without new approaches in public policy, regulati ons and
the educati onal system. We need an overall strategic plan that mirrors the innovati on occurring in our laboratories.

Our positi on of leadership is tenuous. Other regions of the world are investi ng heavily in
laboratory and manufacturing faciliti es while also developing scienti fi c and technical talent
to support biotechnology, thus presenti ng a real and constant threat to the competi -
ti ve advantages of our life sciences super cluster. Our industry needs enlightened public
policy, municipaliti es that welcome biotech faciliti es, collaborati ve relati onships across
the local life sciences community, and the best and the brightest candidates to fi ll jobs
ranging from manufacturing technicians to scienti sts.

The new Life Sciences Initi ati ve, signed into law last year, was certainly a step in the right
directi on. The Life Sciences Initi ati ve will signifi cantly enhance the state’s positi on as the
preeminent desti nati on for the most meaningful research in the biotech fi eld. It will directly
foster research with a fi rst-in-the-nati on centralized repository of new stem cell
lines available to public and private research enterprises. Other programs derived from
the LSI will streamline technology transfer, reduce development ti me and increase funding
opportuniti es. Just as importantly, the initi ati ve will support life science companies
through an improved tax structure, along with grants and loans that will leverage even
more federal and private sector investment. In the midst of this progress, however, illinformed
special interests conti nue to seek legislati on and regulati ons that would place
Massachusett s at a profound disadvantage in the competi ti on to retain and att ract companies that are committ ed to solving unmet medical needs.

 

 

........(계속)